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Alternative splicing of mRNA enables functionally diverse
protein isoforms to be expressed from a single gene, allowing
transcriptome diversification. Interleukin (IL)-24/MDA-7 is a
member of the IL-10 gene family, and FISP (IL-4-induced
secreted protein), its murine homologue, is selectively
expressed and secreted by T helper 2 lymphocytes. A novel
splice variant ofmouse IL-24/FISP, designated FISP-sp, lacks 29
nucleotides from the 5-end of exon 4 of FISP. The level of
FISP-sp expression is 10%of the level of total primary FISP tran-
scription. Unlike FISP, FISP-sp does not induce growth inhibi-
tion and apoptosis. FISP-sp is exclusively localized in endo-
plasmic reticulum, and its expression is up-regulated by
endoplasmic reticulum stress. Our results suggest that the
novel splicing variant FISP-sp dimerizes with FISP and blocks
its secretion and inhibits FISP-induced apoptosis in vivo.
Alternative splicing is a process occurring in eukaryotes,
whereby a pre-mRNA transcribed from one gene can be pro-
cessed into multiple alternative mature mRNA isoforms, thus
leading to the formation of a number of different proteins from
a single gene (1). The number of transcripts generated is medi-
ated by cis-regulatory elements such as the promoter, enhancer,
and repressor control. Alternative splicing regulates the struc-
ture of transcripts, leading to functional diversification. Tran-
script variants generated by alternative splicing are often spa-
tially and/or temporally specific, resulting in effects seen only in
certain cells or developmental stages (2). Alterations in RNA
processing can lead to a variety of human diseases, including
cancer (3).
Alternative splicing is tightly regulated to control certain
stress conditions. The generation of the alternatively spliced
form of HAC-1 (homologue of Apaf-1 and ced-4) or XBP1
(X-box-binding protein 1) is stimulated by the accumulation of
unfolded proteins in the endoplasmic reticulum (ER)2 (3), an
event known as “ER stress.” The spliced form of XBP1 activates
the unfolded protein response (UPR), which actively resolves
ER stress (4). In addition, various studies suggest that alterna-
tive splicing is precisely and efficiently regulated to fulfill spe-
cific tasks (5). Hence, the identification and characterization of
splicing variants generated in specific spatial, temporal, or
stress conditions are likely to increase our understanding of
their functional importance.
Mouse interleukin 24 (mIL-24), also known as FISP (IL-4-
induced secreted protein) was identified by representational
difference analysis during the isolation of genes selectively
expressed in T helper 2 (Th2) cells (6). mIL-24/FISP is a mem-
ber of the IL-10 family alongwith IL-10, IL-19, IL-20, and IL-26,
and it is selectively expressed in Th2 but not Th1 cells. mIL-24/
FISP has significant homology with rat mob-5/c49a (80% to
DNA and 69% to protein) and also with the human melanoma
differentiation-associated gene 7 (IL-24/MDA-7; 89% to DNA
and 93% to protein(7, 8)). Even though mIL-24/FISP is selec-
tively expressed in Th2 cells, its functional role in Th2 cell
development remains unexplored. Many studies have focused
on the anti-cancer activity of IL-24/MDA-7 in various types of
cancers, including melanoma, breast cancer, lung cancer, ovar-
ian carcinoma, cervical carcinoma, colon carcinoma, prostate
carcinoma, hepatoma, pancreatic carcinoma, and osteosar-
coma (9–13). Recent studies have demonstrated that the mIL-
24/FISP gene suppresses the growth of hepatoma cells in vivo
after being delivered via intramuscular electroporation (14),
suggesting that mIL-24/FISP has anti-tumor activity, and that
mIL-24/FISP is truly a homologue of MDA-7.
MDA-7S, a splice variant of MDA-7/IL-24, was identified in
normal human melanocytes, and the loss of the splice variant
expression was associated with metastatic melanoma (15).
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MDA-7SheterodimerizeswithMDA-7but does not influence the
progress ofMDA-7/IL-24-induced cell death.
In this study, we identified a novel splicing variant of mouse
IL-24/FISP from an activated Th2 cell clone (D10). The splice
variant, designated FISP-sp, lacks 29 bp of exon 4 from FISP,
resulting in a frameshift. Thus, FISP-sp mRNA encodes a trun-
cated protein of 158 amino acid residues. Unlike FISP, the cyto-
plasmic localization of the FISP-sp protein appears to be
restricted to the ER. The expression of this novel FISP splice
variant is up-regulated under ER stress in normal cells in vivo.
In addition, FISP-sp dimerizes with FISP and blocks its secre-
tion. Overexpression of FISP-sp reduces FISP-induced growth
inhibition and apoptosis in tumor cells. Our results suggest that
a novel splicing variant of mouse IL-24, FISP-sp, plays an
important role in reducing the FISP-induced ER stress response
in vivo.
EXPERIMENTAL PROCEDURES
RNA Isolation—Total RNAwas isolated from cells using TRI
Reagent (Molecular Research Center) according to the man-
ufacturer’s instructions. The cDNA was synthesized from 1 g
of RNA by reverse transcription using an iScript cDNA synthe-
sis kit (Promega), according to themanufacturer’s instructions.
Quantitative Real Time PCR—A total of 50 ng of cDNA was
used for quantitative real time PCR, following the manufactur-
er’s protocol. Primers specific to FISP and FISP-sp are listed in
Table 1. Primers for used analysis of GADD genes are as fol-
lows: GADD34 (forward) 5-GAC CCC TCC AAC TCT CCT
TC-3 and (reverse) 5-CTTCCTCAGCCTCAGCATTC-3;
GADD45 (forward) 5-TGG TGA CGA ACC CAC ATT
CAT-3 and (reverse) 5-ACCCACTGATCCATGTAGCGA
C-3; GADD153 (forward) 5-ACAGAGGTCACACGCACA
TC-3 and (reverse) 5-GGGCACTGACCACTCTGTTT-3.
The primer pair formouse L32, used as a control, was (forward)
5-GCC CAA GAT CGT CAA AAA GA-3 and (reverse)
5-ATT GTG GAC CAG GAA CTT GC-3. Primers were
designed to span the intron-exon borders, to allow amplified
cDNA to be distinguished from genomic DNA. Quantitative
real timePCRusing a thermocycler (Bio-Rad)was carried out in
a 20-l reaction mixture containing SYBR Green I master mix
(Takara) and 10 pM (each) PCR primers. Samples were dena-
tured at 95 °C for 5 min and were then subjected to 40 cycles of
95 °C for 30 s, 60 °C for 15 s, and 72 °C for 30 s. The final exten-
sion was for 5 min at 72 °C. The authenticity of the PCR prod-
ucts was confirmed by melting curve analysis. The Opticon
Monitor software package 2.0 was used for detection of fluores-
cent signals and for Tm calculations. The PCR-amplified prod-
ucts were electrophoresed in 2% agarose gels and stained with
ethidium bromide.
Plasmid Constructs—The full-length mIL-24/FISP gene
was amplified from a mouse Th2 D10 cell cDNA library with
gene-specific primers incorporating KpnI restriction sites as
follows: FISP forward (5-CGG GGT ACC ATG CTG ACT
GAG CCT GCC C-3) and reverse (5-CGG GGT ACC GAG
ATG GTA GAA TTT CTG CAT CC-3); FISP-sp forward
(5-CGG GGT ACC ATG CTG ACT GAG CCT GCC C-3)
and reverse (5-CGG GGT ACC CTG GGC TGT AGT TGT
GAC AT-3). The reverse primer was designed to delete the
stop codon. The PCR products were purified and inserted
into pcDNA3.1/C-terminal HA, pcDNA3.1 () Myc-His,
and pEGFP-N3, using the KpnI site of these vectors. The
primer positions are based on the mIL-24/FISP sequence,
GenBankTM accession number AF333251.
Cell Lines and Cell Culture—HeLa (human cervical cancer
cell line), B16F10.9 (mouse melanoma cell line), NIH3T3
(mouse embryonic fibroblast), HEK293 (human embryonic
kidney), COS-7 (African green monkey, kidney), and EL-4
(mouse T cell lymphoma) cells were maintained and grown in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum (Hyclone) and 1% penicillin/streptomycin.
The murine Th2 D10 clone (D10.G4.1) was maintained as
described previously (16). CD4 T cells were purified from
spleen and lymph nodes of AKRmice by positive selection with
anti-CD4magnetic beads (Dynal) and differentiated under Th2
conditions according to a standard protocol (17, 18). D10 and
primary Th2 cells were stimulated for 4 h with 1M ionomycin
plus 10 nM PMA. All cultures were maintained at 37 °C in a
humidified 5% CO2 atmosphere.
Transient Transfection and Reporter Assay—Transient
transfections in HEK293 cells were carried out using Lipo-
fectAMINE 2000 (Invitrogen) according to the manufacturer’s
instructions. To analyze whether FISP is degraded via the pro-
teasome, and to prevent proteasomic degradation, HEK293
cells were treated with 10 M MG132 (Sigma), a proteasome
inhibitor, beginning 24 h after transfection for 12 h. For trans-
fection into EL-4 cells, Metafectene (Biontex) was used accord-
ing to the manufacturer’s instructions. For the transfection of
B16F10.9, HeLa, andNIH3T3 cells, the cells were washed twice
with serum-free medium and resuspended in Hypo-osmolar
Electroporation Buffer (Eppendorf), at a concentration of 3 
106 cells/ml. Aliquots of the cell suspension (400l) were trans-
ferred into electroporation cuvettes (2-mm gap width). Cells
were electroporated with 2 g of DNA using a Multiporator
(Eppendorf), according to the manufacturer’s instructions. To
inhibitN-glycosylation and induce ER stress, cells were treated
for 4 h with the ER stress inducer tunicamycin (250 ng/ml),
beginning 20 h after transfection, for 6 h (19). Transient trans-
fections in mouse primary Th2 cells were carried out using
Amaxa Nucleofecter Technology (Amaxa), according to man-
ufacturers’ instructions. Primary Th2 cells (in aliquots of 2 
106) were transfected with 4 g of pXPG vector (20) alone or
with FISP-Luc, FISP-sp-Luc, or screening-Luc (29-SP-
ATG-frame-3-LUC). Six hours after transfection, cells were
stimulated with 1 M ionomycin plus 10 nM PMA for 2 h and
were either left untreated or were further treated with tunica-
mycin for 4 h. To assess luciferase activity, cells were collected,
and lysates were analyzed using the dual luciferase assay system
(Promega). Co-transfection of 100 ng of the pRL-TK vector
(Promega) was used to normalize transfection efficiency, by
measuring Renilla luciferase activity.
Western Blot and Immunoprecipitation Analysis—ForWest-
ern blots, HEK293 cells were harvested and washed in cold
phosphate-buffered saline solution (PBS). Subsequently, cells
were lysed on ice in modified RIPA buffer containing 1% Non-
idet P-40, 50 mM Tris-HCl (pH 7.4), 0.25% sodium deoxy-
cholate, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 10 g/l
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leupeptin, 1 g/l pepstatin, 10 g/l aprotinin, and 1 mM
phenylmethylsulfonyl fluoride. Protein concentrations were
determined by the Bradford method (Bio-Rad). Aliquots con-
taining 30–100 g of total protein were resolved by SDS-
PAGE, using 10–12% polyacrylamide gels, and were trans-
ferred to a nitrocellulose membrane (Protran). To detect the
secreted forms of protein, cells were cultured for 12 h in serum-
free DMEM after 12 h of transfection. Using a Centriprep
device with an Ultracel YM-3 (3,000 nominal molecular weight
limit)membrane (Millipore), the collectedmedium (10ml) was
concentrated into 100l. To the concentrated supernatant was
added 900 l of ice-cold 100% acetone, and the protein was left
to precipitate for 12 h. Protein concentrations were determined
by the Bradford method (Bio-Rad), and 30 g of total protein
was subjected to SDS-PAGE. The following antibodies were
employed to detect proteins: anti-HA.11monoclonal (Covance
Research Products), anti-Myc monoclonal, and anti-GFP
monoclonal (Molecular Probes), anti-ubiquitin (Santa Cruz
Biotechnology), anti-caspase (Abcam), anti-KDEL to detect
GRP-78 and GRP-94 (glucose-regulated protein 78 and 94)
(StressGen), anti-calreticulin (Abcam), and anti-PDI (Santa
Cruz Biotechnology). Anti--actin monoclonal (Santa Cruz
Biotechnology) and anti-glyceraldehyde-3-phosphate dehy-
drogenase (Lab Frontier) antibodies were used for loading con-
trols. For immunoprecipitation analysis, HEK293 cells were
harvested in PBS and incubated in 1 ml of lysis buffer (10 mM
Tris-HCl, 20 mM EDTA, 10 mM NaCl, 0.1 mM phenylmethyl-
sulfonyl fluoride, 10 g/l leupeptin, 1 g/l pepstatin, 10
g/l aprotinin) for 30 min on a rotary shaker at 4 °C. After
centrifugation at 15,000  g for 30 min at 4 °C, supernatants
were incubated with 10 l of 70% protein A-agarose at 4 °C for
1 h to eliminate nonspecific interactions. Samples were centri-
fuged and mixed with anti-Myc and anti-HAmonoclonal anti-
bodies (Molecular Probes) and rotated overnight at 4 °C.
Immunocomplexes were precipitated with 25l of 50% protein
A-agarose for 2 h. The immunoprecipitates were washed very
gently with the immunoprecipitation buffer three times, resus-
pended in 50 l of 10 mM Tris-HCl (pH 8.0) containing 1 mM
EDTA, resolved by SDS-PAGE, and transferred to nitrocellu-
lose membranes. Membranes were blocked with 5% low fat dry
milk in Buffer A (25 mM Tris, 0.15 M NaCl, 0.1% Tween 20 (pH
7.3)) for 1 h at room temperature. Themembranes were immu-
noblotted using the anti-HA.11 monoclonal (Covance
Research Products) and anti-Myc antibodies for co-immuno-
precipitation and the anti-ubiquitin (Santa Cruz Biotechnol-
ogy) antibody for the ubiquitination study in 10 ml of Buffer A
containing 2%milk for 2 h at room temperature. After washing
with Buffer A, the membranes were incubated with mouse IgG
TrueBlotTM at a dilution of 1:1000 in buffer containing 2%milk,
for 1 h at room temperature. Membranes were washed with
Buffer A, developed with ECL reagent (Amersham Bio-
sciences), and exposed to film. Formass spectrometric analysis,
immunoprecipitated samples were resolved by SDS-PAGE and
silver-stained, and the required bands were cut out of the gel
and used for further analysis.
Digestion of Samples for Micro-LC/LC-MS/MS Analysis—
The samples were diluted 5-fold with 50mM ammonium bicar-
bonate (pH 8.0) and 8 M urea, then reduced by adding tris(2-
carboxyethyl)phosphine hydrochloride at room temperature
for 30 min, and then carboxy-amidomethylated in 10 mM
iodoacetamide at room temperature for 30 min in the dark.
Endoproteinase Lys-C (Promega) was added to a final substra-
te:enzyme ratio of 100:1 and incubated at 37 °C for 12 h. The
Lys-C-digested solution was diluted 4-fold with 50 mM ammo-
nium bicarbonate (pH 8.0) followed by the addition of CaCl2 to
2mM.Modified trypsin (Promega) was added to a final substra-
te:enzyme ratio of 100:1. The trypsin digestion was performed
by incubating at 37 °C for 14 h.
Micro-LC/LC-MS/MS Analysis—A single-phase microcapil-
lary column was constructed with 100-mm inner diameter
fused silica capillary tubing pulled to a 5-mm inner diameter tip
using a CO2 laser puller (Sutter Instruments, P-2000). The cap-
illary column was packed sequentially with 7.5 cm of 5-mm
inner diameter Polaris C18-A (Metachem), 4.5 cm of 5-mm
inner diameter Partisphere strong cation exchange (What-
man), followed by another 3.5 cm of Polaris C18-A, using a
homemade high pressure column loader. The columns were
equilibrated with 5% CAN and 0.1% formic acid solution, and
10–25 mg of protein digests were directly loaded onto the cap-
illary column. The buffer solutions used to separate protein
digests were Buffer A (5% ACN and 0.1% formic acid), Buffer B
(80%ACN and 0.1% formic acid), and Buffer C (500mM ammo-
nium acetate, 5% ACN and 0.1% formic acid). Six steps of SCX/
RPLC peptide separation were performed. The first step of 120
min consisted of a 95-min gradient from 0 to 100%Buffer B and
a 25-min hold at 100% Buffer B. The next five steps of 120 min
each were with 55% Buffer B from 15 to 120 min. The Buffer C
percentage in step 2was 5% from 10 to 15min, and in steps 3–6
were 10, 25, 50, and 100%, respectively, from 5 to 9 min. Pep-
tides eluted from the capillary columnwere electrosprayed into
an LCQ Deca XP Plus IT mass spectrometer (Thermo Finni-
gan) with the application of a distal 2.4-kV spray voltage. A
cycle of one full scan (400–1400 m/z) followed by three data-
dependent MS/MS scans at a 35% normalized collision energy
was repeated throughout the LC separation. Bioworks (version
3.1) was used to filter the search results, and the following Xcorr
valueswere applied to the variously charged peptides as follows:
1.8 for singly charged peptides, 2.2 for doubly charged peptides,
and 3.2 for triply charged peptides.
Immunocytochemistry—Both COS-7 and HeLa cells were
fixed in PBS containing 4% formaldehyde and 4% sucrose for 15
min and permeabilized for 5 min in PBS containing 0.25% Tri-
tonX-100. Sampleswere blocked in PBS containing 10%BSA at
37 °C for 30 min and then incubated in PBS containing the
primary antibodies and 3% BSA for 2 h at 37 °C or overnight at
4 °C. The samples were washed six times with PBS and incu-
bated in PBS containing the secondary antibodies and 3% BSA
for 45 min at 37 °C. For Golgi staining, cells were washed six
times in PBS and then incubated in PBS/Hanks’ balanced salt
solution containing Golgi-BODIPY TR Ceramide (Molecular
Probes) for 1 h at room temperature. Coverslips were mounted
on a glass slide, and fluorescence imageswere acquired using an
Olympus IX71 microscope equipped with a 40 N.A. 1.0 or
60 N.A. 1.4 oil lens and a CoolSNAP-Hq CCD camera (Roper
Scientific) driven by MetaMorph (Universal Imaging Corpora-
tion) imaging software. Light from a mercury lamp was shut-
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tered using a VMM1 Uniblitz shutter (Vincent Associates).
Analysis and quantification of data were performed using
MetaMorph software and Sigmaplot, and data were pre-
sented as mean  S.E. Primary antibodies were as follows:
anti-HA (Roche Applied Science), anti-His (Santa Cruz Bio-
technology), and anti-PDI (Molecular Probes). Secondary
antibodies were as follows: Oregon Green-conjugated goat
anti-rabbit (Molecular Probes), Oregon Green-conjugated goat
anti-mouse (Molecular Probes), Texas Red-conjugated goat anti-
rat (Molecular Probes), and Texas Red-conjugated goat anti-
mouse (Molecular Probes).
Cell Growth and Cell Cycle Analysis—Cell growth analysis
experiments were conducted with exponentially, asynchro-
nously growing cells. B16F10.9 mouse melanoma cells were
transfected with vector alone, FISP-myc, FISP-sp-HA alone, or
with combinations of vectors. Cell counts were determined
using a hemocytometer 24, 48, and 72 h post-transfection. For
the assessment of cytotoxicity in response to the addition of the
proteasome inhibitor MG132, HEK293 cells were treated with
increasing concentrations of MG132 (0, 5, 10, 15, and 20 M)
for 12 h. Cell viabilitywas assessed by trypan blue dye exclusion.
For cell cycle analysis, cells were harvested, washed in PBS, and
fixed overnight at20 °C in 70% ethanol. The cells were treated
with RNase A (1 mg/ml) at 37 °C for 30 min and then with
propidium iodide (50 g/ml) (Sigma). The cell cycle was ana-
lyzed using an EXPO32 ADC XL4 Color (Beckman Coulter)
flow cytometer, and data were analyzed with EXPO32 ADC
analysis software (Beckman Coulter).
Hoechst Staining—B16F10.9 cells
were transferred to 6-well plates
after electroporation with a clean
slide and incubated at 37 °C in
humidified 5% CO2 for 48 h. Cells
were washed twice with cold PBS
(pH 7.2) and stained with 0.1
g/ml Hoechst 34580 (Invitrogen)
or propidium iodide (Sigma) at
37 °C for 30 min. Nuclear mor-
phology was observed using a flu-
orescence microscope (Olympus).
DNA Fragmentation Assay—Nu-
cleosomal DNA degradation was
analyzed as described previously
(21) with minor modifications.
Briefly, B16F10.9 mouse melanoma
cells were transfected by electropo-
ration with mock vector, FISP, or
FISP-sp or were co-transfected and
were seeded in 6-well culture dishes.
48 and 72 h post-transfection, cells
were harvested (with trypsinization)
and then lysed in a solution contain-
ing 100 mM NaCl, 10 mM Tris (pH
7.4), 25 mM EDTA, and 0.5% SDS.
After centrifugation, the superna-
tants were incubated with 300
g/ml proteinase K for 5 h at 65 °C
and extracted with phenol/chloro-
form. The aqueous layer was treated with 0.1 volume of 3 M
sodium acetate; the DNA was precipitated with 2.5 volumes of
95% ethanol. After treatmentwith 100mg/mlRNaseA for 1 h at
37 °C, the sample was electrophoresed on a 2% agarose gel at 50
V for 2 h and then stained with ethidium bromide.
RESULTS
Identification of FISP-sp, a Novel Splicing Variant of Mouse
IL-24/FISP—Mouse IL-24/FISP is selectively expressed in Th2
cells (6). During cloning of the mIL-24/FISP gene into a mam-
malian expression vector, we identified a novel splicing variant
of FISP, namely FISP-sp. Initially, total RNA and cDNA were
prepared from D10 cells (mouse Th2-type clone) and stimu-
lated with PMA and ionomycin for 4 h. The cDNA was PCR-
amplified using primer sets spanning the coding region of the
FISP gene. In addition to the FISP-coding sequence fragment, a
slightly smaller sized FISP-coding fragment, FISP-sp, was iden-
tified and cloned (Fig. 1A). Sequencing analysis revealed that
FISP-sp lacks 29 bp from the 5-end of the full-length FISP exon
4 gene (Fig. 1B). This alternative splicing occurs at an A(G/G)T
site, which is the splice site sequence comprising themajor class
of AG-GT introns. The entire FISP-sp sequence was deposited
inGenBankTM accession numberDQ401033. Removal of 29 bp
by splicing activity leads to a frameshift, starting at amino acid
116, and a subsequent translation termination because of a
newly generated stop codon. The predicted primary structure
of FISP-sp contains 158 amino acids, instead of 220 amino acids
as in FISP. FISP-sp and FISP share identical amino acid
FIGURE 1.Cloning of a novel FISP splicing variant, FISP-sp. A, splicing variant of FISP,markedwith an arrow,
was cloned from a D10 cell cDNA library. The difference in the length of FISP-sp and FISP transcripts was
confirmed by PCR. B, DNA sequence alignment of FISP and FISP-sp shows that FISP-sp lacks 29 bp from the
5-end of FISP exon 4. Boxed regions indicate the site of alternative splicing in FISP. Boxed nucleotide sequences
correspond to the sequencing histogram of FISP and FISP-sp. C, FISP and FISP-sp amino acid sequences are
identical at the N-terminal region but are different at the C-terminal region, beginning at the boxed area,
because of a frameshift caused by splicing. Schematic representations of FISP and FISP-sp peptide structures
are shown below the amino acid sequence.
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sequences in their first 115 N-terminal amino acids, but
FISP-sp has a completely different sequence in its 43 C-termi-
nal amino acids, derived from the frame-shifted translation of
the FISP ORF 3 (Fig. 1C).
Quantitation of FISP-sp Expression Levels in T Cells—To
determine the relative expression levels of FISP-sp and FISP, we
performed quantitative real time RT-PCR with four sets of
primer pairs (Fig. 2A, and Table 1). Primers were designed to
detect sequences thatwere (i) common to FISP and FISP-sp (set
1; same amplicon size), (ii) FISP-specific (set 2), (iii) FISP-sp-
specific (set 3; starting from just before the splicing site and
extending to exon 4, and (iv) common to FISP and FISP-sp but
yielding different amplicon sizes because of splicing of 29 bases
(set 4). As shown in Fig. 2D, RT-PCRusing primer set 4 resulted
in PCRproducts of twodifferent amplicons, confirmedbymelt-
ing curve analysis. This result suggests that two transcript iso-
forms with different sizes exist in the T cell cDNA library.
FISP-sp mRNA levels were found to be about 10% of total FISP
mRNA, in both D10 cells (mouse Th2 clone) and primary Th2
cells (Fig. 2, B and C). The specificity of the FISP and FISP-sp
primer sets was confirmed by DNA sequencing and melting
curve analysis (data not shown).
FIGURE2.RelativemRNA levels of FISPandFISP-sp inTh2 cells. ThemRNAexpression levels of FISP andFISP-spwere analyzedbyquantitative real timePCR
in Th2 D10 cells and in 5-day differentiated primary Th2 cells. In quantitative real time PCR amplification, the normalized reporter signal represents the
fluorescence changes adjusted tobase-line levels before amplificationand the threshold cycle (Ct) of amplifiedproducts.A,designedprimer sets are as follows:
common toFISPandFISP-sp (set 1), FISP (set 2), FISP-sp (set 3), and specific forbothFISPandFISP-spbut yieldingampliconsofdifferent sizesbecauseof splicing
of 29 bases (set 4). B, ratio of FISP to FISP-spmRNAwas shown to be10:1 in D10 and Th2 cells. C, threshold cycle of amplified products, whichwere amplified
usingprimer sets 1, 2, and 3.D,melting curve graph for PCRproducts amplified byprimer set 4 demonstrates the presence of twodifferent species of amplified
PCR products. Arrows indicate the relative peaks of FISP and FISP-sp.
TABLE 1
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FISP-sp Is Not Secreted but Is Specifically Localized in ER—
The predicted ORF of FISP and FISP-sp codes 220 and 158
amino acids, respectively (Fig. 1C). Homology between the
FISP-sp protein and full-length FISP is limited to the first 115
amino acids of theN-terminal region. Because FISP-sp contains
the same signaling peptides and cleavage sites as FISP (Fig. 1C),
we tested whether, like FISP, FISP-sp is secreted. To assess pro-
tein secretion, the coding sequences of FISP and FISP-sp were
fused to 3-Myc/His-and 3-HA-tagged vectors, respectively.
These constructs were transiently transfected into HEK293
cells, and the cell lysates and supernatant (serum-free DMEM)
were subjected toWestern blot analysis 24 h post-transfection.
The results revealed that although FISP-sp shares N-terminal
signaling peptides, it is not secreted (there was no signal in the
supernatant fraction) and is exclusively isolated in the cell pellet
(Fig. 3A). Next, the subcellular localization of FISP and FISP-sp
was analyzed in transiently transfected COS-7 cells, 24 h post-
transfection. Expressed FISP (FISP-Myc/His) and FISP-sp
(FISP-sp-HA) were detected using specific antibodies against
their respective C-terminal immunocytochemistry tags. FISP
protein staining was observed in extra-nuclear regions of indi-
vidual cells (Fig. 3B). Although there was a light background of
cytoplasmic staining, FISP protein staining patterns partially
overlapped with the ER and Golgi.
In addition, staining of a mem-
brane-bound form of FISP was
observed. However, the FISP-sp
staining pattern overlapped exactly
and exclusively with the ER (Fig.
3B). FISP localization varied slightly
from that of human IL-24/MDA-7,
which specifically resides in the ER
(22, 23).We also saw similar subcel-
lular localization patterns for FISP
and FISP-sp in HeLa, a human cer-
vical cancer cell line (Fig. 3C).
FISP-sp Antagonizes FISP-in-
duced Inhibition of Cell Growth and
Apoptosis—MDA-7/IL-24 is known
to induce apoptosis in tumor cells
and shows growth-suppressive
activity in a spectrum of human
cancer cells both in vitro and in vivo
(9, 12–14, 24–27). Recently, a
report by Chen et al. (14) showed
that mouse IL-24/FISP mediates
tumor suppression in mice, but the
mechanism of suppression remains
unclear. Until now, little informa-
tion has been available on the role of
MDA-7/IL-24/FISP splicing vari-
ants. To understand the biological
role of FISP-sp in the context of
mIL-24/FISP-induced inhibition of
cell growth, FISP, FISP-sp, or FISP
and FISP-sp together were trans-
fected into the mouse melanoma
cell line B16F10.9. Cell viability was
monitored 24, 48, and 72 h post-transfection by trypan blue dye
exclusion. Overexpression of FISP led to cell growth inhibition
at 24 h post-transfection, and this inhibition was profoundly
increased at 72 h (Fig. 4A) compared with mock vector-trans-
fected cells. This inhibition was comparable with the growth
inhibition induced by tunicamycin. However, FISP-sp did not
induce cell growth inhibition in comparison with vector alone.
Upon co-transfection of FISP and FISP-sp, cell growth was res-
cued in B16F10.9 cells, suggesting that FISP-spmay antagonize
FISP-mediated inhibition of cell growth (Fig. 4A). Because
IL-24 is a potent cancer cell-specific apoptosis-inducing cyto-
kine, we tested whether this growth inhibition by FISP is apo-
ptosis-related. Apoptosis is an active process of self-destruction
associated with profound structural changes, including mor-
phological alteration, increased membrane permeability, and
nuclear collapse, characterized by chromatin condensation and
DNA fragmentation (28, 29). Because growth inhibition by
FISP was maximal at 72 h post-transfection, we began by ana-
lyzing the morphological characteristics of B16F10.9 cells
transfected with mock vector, FISP, FISP-sp alone, or FISP 
FISP-sp together.Microscopic examination revealed that FISP-
transfected cells featured a more prominent nucleus and were
in the later morphological stages of apoptosis (i.e. severe mem-
FIGURE 3. FISP-sp is not secreted but is specifically localized in the ER. A, protein expression of FISP and
FISP-sp. HEK293 cells were transiently transfected with 3-Myc/His-tagged FISP (FISP-Myc/His), 3-HA-tagged
FISP-sp (FISP-sp-HA), or empty vectors (pcDNA 3.1 Myc-His A, and pcDNA 3.1-HA). Protein lysates were col-
lected from cells after transfection with FISP-Myc/His, FISP-sp-HA, or vector alone. Samples (30 g) were used
for Western blot analysis using mouse anti-Myc and anti-HA antibodies. To detect the secreted forms of FISP
and FISP-sp protein, cells were cultured for 12 h in serum-free DMEM. Conditionedmediumwas collected and
concentrated 60-fold. A volume of 20l conditionedmediumwas subjected to SDS-PAGE. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as loading control. B, subcellular localization of FISP and FISP-sp
in COS-7 cells. Protein localizationwas analyzed by immunocytochemistry. FISPwas detected using anti-His or
anti-Myc antibodies, and FISP-sp was detected using an anti-HA antibody. The Golgi and ER were visualized
using Golgi-BODIPY TR ceramide and an anti-PDI antibody. Images of different cellular compartments exhib-
iting FISP and FISP-sp staining were merged. FISP protein staining partially overlapped with ER and Golgi
apparatus staining. However, staining of FISP-sp protein matched exactly with ER staining and was not
detected in the Golgi apparatus. C, subcellular localization of FISP and FISP-sp in HeLa cells.
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brane blebbing; Fig. 4B, upper panel), whereas FISP-sp-trans-
fected cells had intact morphological shapes. Nuclear conden-
sation and DNA fragmentation were detected by Hoechst
staining and fluorescence microscopy in FISP-transfected cells
(Fig. 4B, bottompanel). Unlike FISP, FISP-sp did not induce any
apoptotic characteristics and upon co-transfection decreased
the apoptotic effects of FISP. Similar effects were observed fol-
lowing propidium iodide staining (Fig. 4B, middle panel).
When FISP and FISP-sp were co-transfected, the apoptotic
characteristics induced by FISP were greatly reduced (Fig. 4B).
Flow cytometric analysis was performed after staining cells
with the vital dye propidium iodide. FISP overexpression
increased the level of cell death observed in B16F10.9 cells 24 h
after transfection (sub G0/G1 phase) by 24% (supplemental
Fig. 1). However, FISP overexpression did not induce signifi-
cant levels of cell death in the non-cancer cell line, NIH3T3
cells. Compared with FISP, FISP-sp alone did not induce a sig-
nificant amount of cell death. To examine whether FISP-sp
affects IL-24/FISP-mediated cell death in cancer cells, B16F10.9
cells were co-transfectedwith FISP and FISP-sp, and the level of
FISP-mediated cell death was found to be reduced from 24.26
to 6.47%, raising the possibility that
FISP-sp inhibits FISP-induced cell
death in tumor cells (supplemental
Fig. 1).
A previous report shows that
the GADD family genes, namely
GADD34,GADD45-, andGADD153,
were induced upon adenoviral ex-
pression of MDA-7 (30). Hence, we
investigated whether FISP overex-
pression up-regulates these genes,
and what the role of FISP-sp might
be in this context. B16F10.9 mela-
noma cells were transfected with
mock vector, FISP, FISP-sp, or
FISP  FISP-sp. Total RNA was
extracted, and the mRNA expres-
sion of the GADD family of genes
was analyzed using real time PCR.
As shown in Fig. 4C, the expression
levels of GADD34 and GADD153
gradually increased as apoptosis
progressed in FISP-transfected
cells. At 24 h their levels were low,
but expression increased progres-
sively until 72 h. The level of
GADD45- was significantly in-
creased even after 24 h of FISP
transfection. However, FISP-sp
alone did not induce the expres-
sion GADD34, GADD153 or
GADD45-. Interestingly, co-trans-
fection of FISP-sp with FISP signifi-
cantly reduced the expression levels
of the GADD family genes exam-
ined. A previous report shows that
MDA-7/IL-24 overexpression up-
regulates ER stress markers like BiP/GRP78, GRP94, calreticu-
lin, XBP1, and eIF2 (31).We further evaluated the expression
of ER chaperones whose up-regulation frequently correlates
with UPR resulting from ER stress. We overexpressed FISP,
FISP-sp, or FISP  FISP-sp in HeLa and B16F10.9 cells. 48 h
post-transfection expression of ER stress-response genes was
analyzed. BiP/GRP78, GRP94, calreticulin, and PDI were spe-
cifically up-regulated in B16F10.9 and HeLa cells upon FISP
transfection comparable with tunicamycin-treated cells
(supplemental Fig. 2).This result was in accordance to the
previous report (31). However, FISP-sp did not up-regulate
any of these proteins when transfected alone or when co-
transfected with FISP, and it further blocked their up-regu-
lation (supplemental Fig. 2). These results further substanti-
ate our finding that FISP-sp indeed blocks FISP-induced
apoptosis in cancer cells.
To further test whether FISP induces apoptosis in cancer
cells, we performed a DNA fragmentation assay. B16F10.9 cells
were transfected with mock DNA, FISP, FISP-sp, or FISP 
FISP-sp. To detect internucleosomal DNA fragmentation
(DNA laddering), DNAextracted from the transfected cells was
FIGURE 4. FISP-sp inhibits FISP-induced cell growth inhibition and apoptosis. A, effect of the control
vector, FISP, FISP-sp, and FISP  FISP-sp upon the growth of B16F10.9 cells, analyzed 24, 48, and 72 h post-
transfection. B, apoptotic changes in B16F10.9 cells were analyzed after transfection with mock vector, FISP,
FISP-sp, or FISP FISP-sp. At 72 h post-transfection, photomicrographs were taken of adherent cells in each
sample (upper panel). The cells were then washed and stained with 0.1 g/ml Hoechst 34580 (Invitrogen) or
propidium iodide (Sigma). The slides were then examined by fluorescence microscopy and photographed.
Cells showing signs of apoptosis (fragmented nuclei) and membrane blebbing are shown using Hoechst and
propidium iodide treatment, respectively (bottom and middle panels, respectively). C, overexpression of FISP
induces expression of the GADD family of genes in B16F10.9 melanoma cells, in a time-dependent manner.
Total RNA was extracted, and real time PCR analysis was performed using specific primers. All of the GADD
genes examined were found to be up-regulated in the FISP-transfected samples but not in the samples trans-
fectedwith FISP-sp or FISP FISP-sp.D, B16F10.9 cells were transfectedwith eithermock vector, FISP, FISP-sp,
or FISP FISP-sp. At 48 and 72 h post-transfection, DNA was extracted from the cells, and fragmentation was
analyzed. E, FISP activates caspase-3 in tumor cells. Activationof procaspase-3 is indicatedby thegenerationof
its cleavage products, as observed in FISP-transfected B16F10.9 mouse melanoma cells, but not in FISP-sp-
treated cells. -Actin was used as a loading control.
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separated by agarose gel electrophoresis. As shown in Fig. 4D,
FISP induced significant DNA fragmentation starting at 48 h.
No significant DNA fragmentation was observed at 24 h post-
transfection (data not shown). As expected, FISP-sp did not
induce DNA fragmentation. Co-transfection of FISP and
FISP-sp inhibited FISP-mediated DNA fragmentation (Fig.
4D). To rule out the possibility that the results on induction of
cancer-specific cell death by FISP were because of differing
transfection efficiencies between the NIH3T3 and B16F10.9
cells, the relative expression levels of FISP and FISP-sp were
analyzed by RT-PCR. Their expression levels were similar,
regardless of cell type (supplemental Fig. 3). Because morpho-
logical changes, up-regulation of GADD genes, and increased
fragmentation of DNA were observed in FISP-transfected
B16F10.9 cells, the expression level of caspase-3 was also ana-
lyzed to determine whether processing of procaspase-3 to
active caspase-3 might be activated
by FISP. B16F10.9 cells were trans-
fected with either mock DNA, FISP,
FISP-sp, or FISP  FISP-sp. Levels
of the active form of caspase-3,
generated by the cleavage of
procaspase-3, were increased in
FISP-transfected but not in FISP-
sp-transfected cells (Fig. 4E). Co-
transfection of FISP and FISP-sp
reduced the generation of caspase-3
by FISP (3rd lane in Fig. 4E). These
results show that FISP inhibits cell
growth and induces apoptosis in
B16F10.9 cells by activating cell sig-
naling molecules associated with
apoptosis, resulting in cell death.
However, these FISP-mediated
effects appear to be reduced or
absent when FISP is co-expressed
with its splicing variant, FISP-sp.
These results are in accordancewith
previous studies, which report that
the growth-suppressive activities of
IL-24/MDA-7 are restricted to mel-
anoma cells and are not observed in
normal fibroblasts or in epithelial
cells (8, 30, 32). Our results suggest
that FISP is a true homolog of
human IL-24/MDA-7 with growth-
inhibitory effects specific to cancer
cells and that FISP-sp inhibits this
property of FISP.
FISP-sp Heterodimerizes with
FISP, Leading to Its Retention in the
ER—Next, the molecular mecha-
nism of FISP-sp-mediated inhibi-
tion of FISP function was examined.
IL-24 is a tumor suppressor gene
that functions as a cytokine, and it is
secreted both by normal cells and by
cancer cells upon adenoviral delivery
(33–36).The significant bystander activity of secreted IL-24 iswell
documented (13, 25, 34, 37–41). A previous report suggested that
anovel splice variantof IL-24,MDA-7S,decreased the secretionof
human IL-24/MDA-7 inmelanocytes viaphysical interaction (15).
Hence, we attempted to determine whether FISP-sp inhibits
the secretion of FISP, as FISP-sp itself is not secreted. West-
ern blot analysis revealed that upon FISP  FISP-sp
co-transfection, FISP-sp completely blocked FISP secretion
(Fig. 5A). We next investigated whether there exists any
physical interaction between FISP and FISP-sp. Following
immunoprecipitation and Western blot analysis in HEK293
cells co-transfected with FISP and FISP-sp expression vec-
tors, FISP and FISP-sp were found to interact (Fig. 5B). This
interaction appeared to alter FISP localization, causing FISP
to be localized exclusively in the ER, along with FISP-sp, both
in COS-7 and HeLa cells (Fig. 5C).
FIGURE 5. Physical interaction of FISP and FISP-sp. A, FISP-sp blocks FISP secretion. HEK293 cells were
transiently transfected with 3-Myc/His-tagged FISP (FISP-Myc/His) or 3-HA-tagged FISP (FISP-HA), or their
respective empty vectors (pcDNA 3.1 Myc-his A, and pcDNA 3.1-HA). To detect the secreted forms of these
proteins, cells were cultured for 12 h in serum-free DMEM. Conditioned medium was collected, concentrated
100-fold, precipitatedwith 100% acetone, and subjected to SDS-PAGE andWestern blot analysis usingmouse
anti-Myc and anti-HA antibodies. IB, immunoblot. B, FISP-sp physically interacts with FISP. HEK293 cells were
transiently transfected with 3-Myc/His-tagged FISP (FISP-Myc/His) or 3-HA-tagged FISP-sp (FISP-sp-HA)
expression vectors. Immunoprecipitation analysis was performed 24 h post-transfection using anti-Myc, anti-
HA, or anti-IgG (control) antibodies, and the samesampleswere further analyzedusingWesternblot analysis as
indicated. FISP and FISP-sp bands are indicated by arrows. C, subcellular localization of FISP and FISP-sp upon
expression vector co-transfection in COS-7 and HeLa cells. Protein localization was analyzed by immunocyto-
chemistry. FISPwas detected using anti-His or anti-Myc antibodies, and FISP-spwas detected using an anti-HA
antibody. The ER was visualized using an anti-PDI antibody. Images of ER compartments and FISP or FISP-sp
staining were merged. The pattern of FISP protein staining overlapped exactly with that of FISP-sp staining in
the ER compartment, in both inCOS-7 andHeLa cells.D,HEK293 cellswere transfectedwith 3-Myc/His-tagged
FISP (FISP-Myc/His) or 3-HA-taggedFISP-sp (FISP-sp-HA), orwere co-transfectedwithbothexpression vectors.
MG132 (10M) was added to cells 24 h post-transfection or cells were left untreated. Cells were analyzed 12 h
later by Western blot analysis using anti-Myc or anti-HA antibodies. Bands corresponding to FISP and FISP-sp
are indicated by arrows.
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Proteasomal Degradation of FISP upon Interaction with
FISP-sp—The ubiquitin proteolytic system plays an important
role in a broad array of basic cellular processes (42). The list of
cellular proteins targeted by ubiquitin is growing rapidly.
Among them are cell cycle regulators, tumor suppressors and
growth modulators, transcriptional activators and their inhibi-
tors, cell surface receptors, and endoplasmic reticulumproteins
(43). Because co-expression of FISP and FISP-sp causes FISP to
be retained in the ER, and inhibits its secretion, rendering it
functionally inactive, we further queried the fate of the retained
FISP protein. The possibility was investigated that inactivation
of FISPmight lead to its degradation via the proteasome. In cells
co-transfected with FISP  FISP-sp expression vectors, treat-
ment with the proteasome inhibitor MG132 showed increased
accumulation of FISP (Fig. 5D), whereas there was no change in
FISP levels in cells transfected only with the FISP-containing
vector. FISP-sp levels did not differ significantly between sam-
ples transfected with FISP-sp alone or FISP-sp FISP. As such,
it appears that FISP is recruited to the proteasome and is pos-
sibly ubiquitinated, in the presence of expressed FISP-sp. The
possible cytotoxic effect of MG132 upon HEK293 cells was
investigated by treating cells with increasing concentrations of
MG132 (0, 5, 10, 15, and 20 M) for 12 h (supplemental Fig. 4).
Cell viability remained greater than 90% after treatmentwith 10
M MG132 for 12 h. Further analysis of whether the FISP pro-
tein was ubiquitinated was undertaken using immunoprecipi-
tation assays. Ubiquitinated FISP was detected in FISP 
FISP-sp co-transfected cell lysates between 17 and 25 kDa (sup-
plemental Fig. 5). The 25-kDa fraction of the IL-24 protein
overlapped with the light chain of immunoglobulin G and
hence could not be separately distinguished. However, the
intensity of the 25-kDa band in the co-transfected cells (lane 3
of left panel in supplemental Fig. 5) was increased relative to
that of the FISP-transfected cells (lane 2 of left panel in supple-
mental Fig. 5), indicating the presence of ubiquitinated FISP
protein with a molecular mass of25 kDa. Proteomic analysis
was performed to identify FISP-sp/FISP-interacting proteins
(supplemental Table 1). Along with the FISP and FISP-sp pep-
tides, peptides of various proteins involved in ubiquitination
were detected, including ubiquitin-activating enzyme and
ubiquitin-conjugating enzyme alongwith other proteins having
important roles in the ubiquitin-proteasome pathway (43).
These results suggest that FISP is ubiquitinated and that treat-
ment with MG132 results in its accumulation.
Expression of FISP-sp Is Increased under ER Stress—Accumu-
lation of unfolded or misfolded proteins in the ER induces a
cellular state of ER stress, which in turn induces apoptosis. ER
stress is known to be involved in the pathogenesis of diverse
humandiseases. Recent studies have shown that the anti-tumor
activity of MDA-7/IL-24 in cancer cells is associated with ER
stress-mediated cytotoxicity and up-regulation of ER stress-in-
duced GRP78/BiP expression (26, 27, 31). A report by Gupta et
al. (23) shows that human IL-24/MDA-7 physically interacts
with BiP/GRP78 through its C and F helices and induces can-
cer-selective apoptosis, but the exact mechanism of FISP-in-
duced inhibition of cell growth is unclear.
Based on the findings that FISP-sp inhibits FISP-induced
apoptosis and growth inhibition in tumor cells (Fig. 4), we
hypothesized that FISP-sp expression could be up-regulated
upon ER stress to serve as a defense mechanism, rescuing nor-
mal cells from FISP-mediated growth arrest. Vector systems
were designed, to quantitatively assess the generation of
FISP-sp under conditions of ER stress, by monitoring a GFP or
luciferase signal. The mouse IL-24/FISP gene was fused to the
GFP or LUC gene in such a way that the generation of func-
tional GFP or luciferase was splicing-dependent. Shown in Fig.
5A are the vectors 29-SP-ATG-frame3-GFP and 29-SP-
ATG-frame3-LUC, which contain the full-length IL-24/FISP
gene fused into the reading frame-3 of GFP or luciferase,
respectively. When mIL-24/FISP mRNA was spliced to create
FISP-sp mRNA, the 3-tagged GFP or luciferase fusion gene
would be functionally expressed as FISP-sp-GFP or FISP-sp-
LUC protein, respectively, because of an in-frameshift (from
reading frame 1–3). However, if splicing did not occur, the
3-tagged GFP or luciferase fusion protein would not be
expressed, since translation of the frame 1-encoded protein
would stop before reaching the GFP start codon. To eliminate
GFP false-positive signals, the start codon of GFP was deleted
by site-specific deletion mutagenesis (Fig. 6A).
To test whether the generation of FISP-sp is ER stress-de-
pendent, we overexpressed the 29-SP-ATG-frame3-GFP
and 29-SP-ATG-frame3-LUC vectors through transient
transfection into HEK293, NIH3T3, B16F10.9, HeLa, and EL-4
cells. Analysis of HEK293 and EL-4 cells transfected with the
29-SP-ATG-frame3-LUC vector revealed a 1.5-fold
increase in gene activity upon treatment with the ER stress
inducer tunicamycin (2 g/ml, inhibits protein N-glycosyla-
tion) in comparisonwith untreated samples, suggesting that ER
stress plays a role in inducing expression of the splicing variant
FISP-sp (Fig. 6B). NIH3T3 cells transfected with 29-SP-
ATG-frame3-GFP showed an increase in the number of GFP-
positive cells when treated with tunicamycin (2g/ml). The ER
stress-dependent levels of GFP expression were determined by
Western blot analysis using a monoclonal GFP antibody (Fig.
5B). Removal of 29 bp by splicing was predicted to lead to the
expression of a GFP-tagged protein the same size as FISP-sp-
GFP (Fig. 6B, 1st lane). Indeed, as shown in Fig. 6B, bands cor-
responding to FISP-sp-GFP were detected in the 2nd and 3rd
lanes and were notably increased by ER stress. In addition, GFP
expression (27 kDa) was observed only in samples treated with
tunicamycin, suggesting that generation of functional GFP was
because of induction of the splicing variant in conditions of ER
stress (Fig. 6B, 3rd lane). Similar results were obtained in cells
treated with thapsigargin (500 nM), which inhibits Ca2
ATPase in the ER (data not shown).
To further confirm the above results, levels of FISP-sp
mRNA were measured using quantitative real time RT-PCR
with specific primer sets (primer set 5 and 6, see Table 1) for
FISP and FISP-sp (Fig. 6C and Table 1). NIH3T3 cells were
transfected with 29-SP-ATG-frame3-GFP or vector alone
and treated with or without tunicamycin. Similarly, EL-4 cells
were transfected with 29-SP-ATG-frame3-LUC or vector
alone. Total RNA was extracted and cDNAs were synthesized,
as described under “Experimental Procedures.” A slight (1.8-
fold) increase in FISP mRNA levels was observed under condi-
tions of ER stress, as compared with the levels observed in
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untreated NIH3T3 cells (data not shown). However, the
FISP-sp mRNA levels increased10- and 13-fold in tunicamy-
cin-treated NIH3T3 and EL-4 cells, respectively, when com-
pared with untreated cells (Fig. 6C). These data suggest that
conditions of ER stress lead to the generation of FISP-sp and
clearly demonstrate that ER stress plays a crucial role in the
generation of FISP-sp in normal cells. As such, increased
FISP-sp levels might be involved in rescuing cells from ER
stress-induced cell death.
We further analyzed the effect of ER stress on FISP-sp syn-
thesis in primary T cells. CD4 cells purified frommouse spleen
and lymph node were differentiated in vitro into Th2 cells over
a period of 6 days and then were transfected with 29-SP-
ATG-frame3-LUC or mock vector. A luciferase assay
revealed only a 1.5-fold increase in luciferase activity, indicating
that FISP-spwas generated upon induction of ER stress in29-
SP-ATG-frame3-LUC-transfected cells (Fig. 6D). However,
there was a dramatic 25-fold enhancement in levels of
FISP-spmRNAupon induction of ER stress, whereas only basal
levels of expression were observed in cells transfected with vec-
tor alone or those not receiving ER stress induction, demon-
strating the strong involvement of ER stress in the generation of
FISP-sp in vivo (Fig. 6D). To further test whether FISP-sp
mRNA levels or splicing-dependent luciferase activity were
increased in cancer cells such as B16F10.9 and HeLa cells, a
luciferase assay was undertaken (Fig. 6E, left). No increase in
FISP-sp levels was observed following ER stress induction in
HeLa cells, whereas in B16F10.9 cells, a 40%decrease in FISP-sp
levels was observed. Similarly, a 75% decrease in FISP-sp
mRNA levels was observed following ER stress induction in
B16F10.9 cells, with only basal levels seen in cells transfected
with vector only (Fig. 6E, right). These results suggest that the
FIGURE 6.Generationof FISP-spunder conditions of ER stress.A, schematic representations of protein structures resulting from the29-SP-ATG-frame3-
GFP and29-SP-ATG-frame3-LUC vectors. B, HEK293 and EL-4 cells were transfected with the29-SP-ATG-frame3-LUC vector or with the pXPG vector as
a control (mock). Higher levels of luciferase activity were observed in tunicamycin-treated samples, compared with untreated samples. NIH3T3 cells were
transiently transfected with the29-SP-ATG-frame3-GFP vector. Anti-GFPmonoclonal antibodies were used for Western blot analysis. Bands matching the
size of the expressed FISP-sp-GFP proteinweremore pronounced in their intensity, in cells treatedwith tunicamycin. C, cDNA from29-SP-ATG-frame3-LUC
or vector only. TransfectedNIH3T3 andEL-4 cells left untreatedor treatedwith tunicamycinwereprepared and analyzedbyquantitative real timePCRanalysis.
Expression levels in untreated (w/o) samples were assigned a value of 1. The fold change in FISP-sp expression upon tunicamycin treatment was determined
by comparison of treated and untreated samples. D, transient transfections in mouse primary Th2 cells were carried out, and luciferase activity was analyzed.
Cells were collected, and lysates were assessed using the dual luciferase assay system. Analysis of mRNA levels revealed a 25-fold increase upon induction of
ER stress. Expression levels in untreated (w/o) samples were assigned a value of 1. The data are representative of at least two independent experiments.
E, transient transfections in B16F10.9 and HeLa cells were performed, and analysis of luciferase activity was performed as described above. Analysis of mRNA
levels revealed a 75% decrease upon induction of ER stress in B16F10.9 cells. The data are representative of at least two independent experiments.
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cancer cell machinery might inhibit the generation of the
FISP-sp protein, thereby rendering tumor cells more suscepti-
ble to FISP-induced apoptosis.
DISCUSSION
Alternative splicing of pre-mRNA generates two or more
protein isoforms from a single gene, thereby generating protein
diversity. Recent studies have suggested that splicing variants
play a regulatory role in controlling the function and/or activity
of their full-length counterparts (44). In this study, we have
identified a novel splicing variant of mouse IL-24/FISP, desig-
nated it with the name FISP-sp, and characterized its subcellu-
lar localization and biological function. Alternative splicing of
29 nucleotides at the 5-end of exon 4 of FISP induces a frame-
shift and leads to premature termination of wild type mouse
IL-24/FISP at amino acid 158 instead of amino acid 220.
Expression of FISP-sp is increased under ER stress. Unlike FISP,
FISP-sp is specifically localized in the ER and antagonizes the
growth inhibition, ER stress induction, and apoptosis induced
by FISP. FISP-sp physically interacts with FISP, which retains
FISP in the ER, and subsequently leads to degradation of FISP
by the proteasome.
Mouse IL-24/FISP is classified as an IL-10 cytokine family
member (38) based on its chromosomal location, sequence, and
structure homology. Like other IL-10-related cytokines, mIL-
24/FISP is a secreted -helix protein. Although its function has
not yet been elucidated, it is thought that FISP might play an
important role in the immune systemas a cytokine. FISP-sp, the
novel splicing variant identified here, loses its homology with
FISP in the C terminus, a region of FISP that includes half of the
IL-10 signature sequence (AHSLLKFYLNTVFKNYHSKI-
AKFK) and the helix C to F domain. Unlike mIL-24/FISP,
FISP-sp is not secreted and is specifically localized in the ER,
suggesting that it might not function as a cytokine but rather
might exert its activity in the ER in the context of FISP expres-
sion. In cells, splicing variantsmay be generated by simple splic-
ing errors, and such proteins are normally degraded by a proc-
ess termed nonsense-mediated decay (NMD) (1). NMD occurs
when a transcript contains a stop codon in a positionmore than
50–55 nucleotides upstream of the 3-most exon-exon junc-
tion, in which case polysome-associated Upf proteins interact
with the exon-junction-protein complex to elicit NMD. In con-
trast, if translation terminates within 50–55 nucleotides
upstream of the 3-most exon-exon junction or downstream of
the junction,mRNAappears to be protected against NMD (45).
Based on these parameters, FISP-sp is a product of alternative
3-splice site splicing, which represents8% of total alternative
splicing events and is not classified as a splicing error (5). In
addition, FISP-sp splicing occurs at an A(G/G)T site, which
includes themajor class of splicing site sequences (3). Although
FISP-sp mRNA contains a premature stop codon, this stop
codon is located at the junction of exon 4 and exon 5. Thus, the
transcript is not detected as a target for NMD, and FISP-sp
protein is maintained in the cell.
RT-PCRanalysis shows that the FISP-sp expression levels are
10% of the levels of full-length IL-24/FISP. FISP-sp is localized
predominantly in the ER. Overexpression of FISP-sp and FISP
together reduced the growth inhibition and apoptosis induced
by IL-24/FISP in tumor cells. Analysis of various apoptotic
characteristics revealed that FISP-sp not only rescues FISP-in-
duced growth inhibition but also, remarkably, blocks apoptosis
induced by FISP (Fig. 4). It was also found that FISP-sp is not
secreted, andmultiple FISP-sp protein bands detected byWest-
ern blot analysis suggest that FISP-sp is highly glycosylated, like
FISP. However, because of FISP-sp frameshift splicing, three
putative N-glycosylation sites, asparagine residues at amino
acid positions 170, 195, and 208, are eliminated, and the glyco-
sylation patterns of FISP and FISP-sp might differ. Not only is
FISP-sp completely localized in the ER but it also blocks
secretion of FISP completely, thereby antagonizing the most
important property of FISP as a cytokine with bystander
antitumor activity. The inhibition of FISP secretion, the
physical interaction of FISP and FISP-sp, and the ER reten-
tion of FISP are features that point toward a mechanism by
which FISP is exclusively regulated under ER stress condi-
tions (Fig. 5). Further analysis of the fate of the retained FISP
protein, via treatment with MG132, a potent proteasome
inhibitor, suggested that FISP is efficiently recruited to the
proteasome for degradation (Fig. 5D). To test whether this
degradation is mediated by recruitment of ubiquitin, FISP-
transfected and FISP FISP-sp co-transfected samples were
immunoprecipitated with their respective antibodies and
analyzed by Western blot using an anti-ubiquitin antibody.
Although no dramatic differences were observed, the FISP
band appeared to be more prominent in samples from co-
transfected cells (supplemental Fig. 5). Protein bands over-
lapping the IgG light chain (25 kDa) and lower bands around
17 kDa were more prominent in comparison with the sam-
ples from cells transfected with FISP only (supplemental Fig.
5). Proteomic analysis identified peptides of proteins
involved in ubiquitination, including ubiquitin-activating
enzyme E1 and ubiquitin-conjugating enzyme E2 to be FISP-
sp/FISP interacting proteins (supplemental Table 1). We
also detected the peptides of ubiquitin-specific peptidase 9,
which is a deubiquitinating enzyme (46), and LOC629750, a
protein similar to ubiquitin A-52 residue ribosomal protein
fusion product 1. This protein acts as a protein modifier that
can be covalently attached to target lysines, either as a mon-
omer or as a lysine-linked polymer, leading to their degrada-
tion by the proteasome. We also detected the peptides of
transitional endoplasmic reticulum ATPase (VCP). VCP is a
component of a complex that binds ubiquitinated proteins
and is necessary for the export of misfolded proteins from
the ER to the cytoplasm, where they are degraded by the protea-
some(48).Detectionof theaboveproteins incomplexwithFISPor
FISP-sp indicates an association between FISP and FISP-sp in the
ubiquitination-mediated proteasomal degradation pathway.
Along with unique peptides of FISP-sp and FISP that verify the
interaction of FISP and FISP-sp (data not shown), the detection of
peptides of twomajor splice factors, Spfq (proline- and glutamine-
rich) and Sprs9 (arginine/serine-rich 9), further supports this
interaction and provides a glimpse into the mechanism whereby
FISP-sp is generated, and the manner in which FISP and FISP-sp
are regulated.
Our results corroborate those recently reported by Gopalan
et al. (49) demonstrating ubiquitination and subsequent 26 S
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proteasome-mediated degradation ofMDA-7 in cancer cells. In
addition, inhibition of ubiquitination reportedly led to
enhanced killing of cancer cells, an effect thatmight result from
accumulation of IL-24 protein. In normal cells, however, FISP
degradation might be mediated by its splicing variant FISP-sp,
which is up-regulated in stress conditions. Further studies are
needed to understand the precise relationship between FISP,
FISP-sp, and the ubiquitin-proteasome system.
According to quantitative real time RT-PCR analysis,
FISP-sp is expressed at 10% of the total level of primary FISP
transcripts detectable in mouse Th2 cells (Fig. 1), which sug-
gests that FISP-sp and FISP coexist. Hence, we propose that
FISP-sp function might not be independent of FISP but might
instead be coordinated to support or regulate FISP. This idea is
strengthened by considering the following question. If apopto-
sis is caused by IL-24/MDA-7-induced ER stress in T cells, how
does a similar accumulation of intracellular IL-24 protein in
normal T cells during Th2 lymphocyte differentiation occur
without eliciting apoptosis? We hypothesize that FISP-sp is
generated in response to FISP-induced ER stress and that it acts
to regulate FISP function by blocking ER stress and subse-
quently apoptosis. In this study, we have shown that FISP-sp
levels can be increased by ER stress in NIH3T3 cells and EL-4
cells, as well as in primary Th2 cells, but not in mouse mela-
noma B16F10.9 cells. These results suggest that the cellular
machinery in cancer cells can inhibit the formation of FISP-sp
upon ER stress induction (Fig. 6E). Transient reporter assays
also show a significant increase in FISP-sp levels upon ER stress
induction. Moreover, when FISP-sp was co-transfected with
FISP, the cell growth inhibition induced by FISPwas nullified. It
is interesting to note that although overexpressed FISP-sp is
localized and accumulated in the ER, unlike FISP it does not
induce apoptosis. Unlike FISP, overexpression of FISP-sp alone
did not up-regulate ER stress-associated ER chaperones like
BiP/GRP78, GRP94, calreticulin, and PDI (supplemental Fig. 2)
in B16F10.9 and HeLa cells. FISP-sp rather down-regulated
FISP-mediated up-regulation of ER stress-responsive genes,
indicating that FISP-sp generation may be a normal physiolog-
ical process to resolve the ER stress without any negative side
effects. These observations seem to contradict the idea that
IL-24/MDA-7-mediated apoptosis is caused by its massive
accumulation in the ER and raises the question of why IL-24/
MDA-7 induces apoptosis in cancer cells but not in normal
cells. In other words, if IL-24/MDA-7 induces ER stress in can-
cer cells, then normal cells would be expected to be similarly
affected by ER stress.
Nonconventional mRNA splicing is a well known mecha-
nism bywhich cellular survival against ER stress is improved. In
the case of IRE1-mediated alternative splicing, as reported in
yeast HAC1 and human XBP1 transcripts, mRNA introns are
spliced by IRE1 endonucleolytic cleavage activity. Under con-
ditions of ER stress, activated IRE1 removes a 26-nucleotide
intron fromnativeXbp1mRNA.This splicing event generates a
frameshift, producing a protein that activates theUPR,which in
turn efficiently resolves the ER stress (50).We speculate that
alternative splicing and generation of FISP-sp is a survival
mechanismagainst FISP-inducedER stress, and that thismech-
anism is maintained in normal cells but is dysfunctional in
tumor cells. The proportional balance of FISP and FISP-sp
expression levels may play a central role in normal cell devel-
opment. We assume that this is one reason for the observation
that FISP induces apoptosis in B16F10.9 cells but not in
NIH3T3 cells. Indeed, we did not observe any increase in
FISP-sp mRNA levels or FISP-sp protein splicing-dependent
luciferase activity in B16F10.9 cells (Fig. 6E), which presumably
renders the tumor cells more susceptible to FISP-induced
growth inhibition.Uponoverexpression of the29-SP-ATG-
frame3-GFP vector inNIH3T3 cells, GFP signalswere detected.
Similarly, in HEK293 and EL-4 cells, certain levels of reporter
gene activity were found even in untreated cells, but the levels
increased when cells were treated with the ER stress inducers
tunicamycin and thapsigargin. These results suggest that
NIH3T3, HEK293, and EL-4 cells have amechanism of splicing
FISP mRNA to form FISP-sp under naturally occurring condi-
tions of FISP-induced ER stress. In contrast, B16F10.9 cells lack
any ability to generate FISP-sp, and thus fail to control ER stress
successfully, leading to FISP-induced apoptosis. Moreover, we
demonstrated that FISP-sp is generated or up-regulated by
FISP-inducedER stress duringTh2 cell development.However,
whether splicing of FISP to FISP-sp is mediated by IRE1
remains to be tested. The exact mechanism of the failure of
tumor cells to inhibit FISP-sp function, which leads to their
growth inhibition, remains unclear. Considering the recent
report by Gupta et al. (23), demonstrating the physical interac-
tion between IL-24/MDA-7 and the ER chaperone BiP/GRP78,
further studies are needed to determine whether FISP is
involved in such an interaction and to exactly define the bio-
chemical nature of FISP-sp andwhether FISP-sp interfereswith
this interaction to prevent cell death in normal cells.
In summary, we have identified a novel splicing variant of
FISP, named FISP-sp, and characterized its induction, subcel-
lular localization, and function as an antagonist of FISP. Our
observations, reported here, provide in vivo evidence of ER
stress-mediated generation and up-regulation of FISP-sp.
These findings contribute to our understanding of the physio-
logical regulation of splicing and the functional relationships
between splicing product isoforms.
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